103 Results

People

  1. Lesokhin
    Lesokhin
  2. Brentjens
    Brentjens
  3. Scheinberg
    Scheinberg
  4. Riviere
    Riviere
  5. Sadelain
    Sadelain
  6. Park
    Park
  7. Wang
    Wang
  8. Korde
    Korde
  9. Landgren
    Landgren
  10. Maslak
    Maslak

Groups

  1. Center for Hematologic Malignancies (103)
  2. Hematologic Malignancies Research (103)
  3. Department of Medicine (100)
  4. Hematologic Malignancies, Division of (96)
  5. GSK Faculty (70)
  6. Sloan Kettering Institute Faculty (48)
  7. Adult Leukemia (46)
  8. Molecular Pharmacology and Chemistry Program Faculty (46)
  9. Myeloma (42)
  10. Tow Center for Developmental Oncology (TCDO) (30)
  1. "Hematologic Malignancies Research"
  2. "American Society of Clinical Oncology"
  3. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (75)
  2. Journal Article (28)
Groups
  1. Center for Hematologic Malignancies (103)
  2. Hematologic Malignancies Research (103)
  3. Department of Medicine (100)
  4. Hematologic Malignancies, Division of (96)
  5. GSK Faculty (70)
  6. Sloan Kettering Institute Faculty (48)

More Groups

People
  1. Alexander Lesokhin (34)
  2. Renier Brentjens (26)
  3. David Scheinberg (21)
  4. Isabelle Riviere (19)
  5. Michel Sadelain (19)
  6. Jae Park (16)

More People

Years
  1. 2023 (12)
  2. 2022 (8)
  3. 2021 (4)
  4. 2020 (3)
  5. 2019 (5)
  6. 2018 (6)

More Years

Publications
  1. Journal of Clinical Oncology (99)
  2. American Society of Clinical Oncology Educational Book (2)
  3. JCO Clinical Cancer Informatics (1)
  4. JCO Precision Oncology (1)
Publishers
  1. American Society of Clinical Oncology (103)

Results (103)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent
    Meeting Abstract

    Kumar, S.; Bachier, C. R.; Cavo, M.; Corradini, P.; Delforge, M.; Janowski, W.; Lesokhin, A. M.; Mina, R.; Paris, L.; Rosiñol, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES)
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S. Z.; Lesokhin, A. M.; Moysich, K. B.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Meeting Abstract

    Tomasson, M. H.; Bahlis, N. J.; Costello, C.; Raje, N. S.; Levy, M. Y.; Dholaria, B. R.; Solh, M. M.; Damore, M. A.; Jiang, S.; Xie, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of bay 18953444 (elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112
    Meeting Abstract

    Ortiz, M. V.; Glade Bender, J. L.; Minard, C. G.; Liu, X.; Denic, K. Z.; Reid, J. M.; Militano, O.; Church, A. J.; Kentsis, A.; Reynolds, C. P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort
    Meeting Abstract

    Parikh, R.; Castro, F.; Eustaquio, J. C.; Derkach, A.; Joseph, J.; Lesokhin, A. M.; Usmani, S. Z.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raje, N. S.; Leleu, X. P.; Lesokhin, A. M.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant
    Meeting Abstract

    Shah, G. L.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D. J.; Gupta, G. K.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T. G.; Usmani, S. Z.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save